| Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators RA Coleman, CS Muli, Y Zhao, A Bhardwaj, TR Newhouse, DJ Trader Bioorganic & medicinal chemistry letters 29 (3), 420-423, 2019 | 27 | 2019 |
| Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor MP Huestis, D Dela Cruz, AG DiPasquale, MR Durk, C Eigenbrot, ... Journal of Medicinal Chemistry 64 (7), 3940-3955, 2021 | 21 | 2021 |
| Synthesis of sugar oxime ether surfactants HS Ewan, CS Muli, S Touba, AT Bellinghiere, AM Veitschegger, TB Smith, ... Tetrahedron Letters 55 (35), 4962-4965, 2014 | 18 | 2014 |
| Small‐Molecule Inhibitors of the Proteasome's Regulatory Particle CS Muli, W Tian, DJ Trader ChemBioChem 20 (14), 1739-1753, 2019 | 17 | 2019 |
| Optimization and Anti-Cancer Properties of Fluoromethylketones as covalent inhibitors for Ubiquitin C-terminal Hydrolase L1 AD Krabill, H Chen, S Hussain, CS Hewitt, RD Imhoff, CS Muli, C Das, ... Molecules 26 (5), 1227, 2021 | 8 | 2021 |
| N-Terminal Targeting of Regulator of G Protein Signaling Protein 2 for F-Box Only Protein 44–Mediated Proteasomal Degradation HJ McNabb, S Gonzalez, CS Muli, B Sjögren Molecular Pharmacology 98 (6), 677-685, 2020 | 8 | 2020 |
| Natural product-inspired molecules for covalent inhibition of SHP2 tyrosine phosphatase W Liang, AD Krabill, KS Gallagher, C Muli, Z Qu, D Trader, ZY Zhang, ... Tetrahedron 156, 133918, 2024 | 4 | 2024 |
| Discovery and Development of Cyclic Peptide Proteasome Stimulators S Nelson, TJ Harris, CS Muli, ME Maresh, B Baker, C Smith, C Neumann, ... ChemBioChem 25 (3), e202300671, 2024 | 3 | 2024 |
| Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor MP Huestis, MR Durk, C Eigenbrot, P Gibbons, TL Hunsaker, H La, ... ACS Medicinal Chemistry Letters 12 (5), 791-797, 2021 | 3 | 2021 |
| Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1 RD Imhoff, R Patel, MH Safdar, HBL Jones, A Pinto-Fernandez, I Vendrell, ... Journal of Medicinal Chemistry 67 (6), 4496-4524, 2024 | 2 | 2024 |
| 20S proteasome hydrolysis of LLVY substrates to determine preferences for moieties in its primed substrate channel CS Muli, DJ Trader Bioorganic & medicinal chemistry letters 85, 129233, 2023 | 2 | 2023 |
| Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers CA Loy, CS Muli, EMH Ali, D Xie, MH Ahmed, CB Post, DJ Trader Bioorganic & Medicinal Chemistry Letters 95, 129485, 2023 | 1 | 2023 |
| The physico-chemical properties of sugar-oxime-ether surfactants RK Rowe, KR Matasci, AR Rickelmann, CS Muli, EE Doherty, TB Smith, ... Tenside Surfactants Detergents 57 (1), 6-12, 2020 | 1 | 2020 |
| PEPTIDOMIMETIC APPROACHES FOR TARETING PROTEASOME SUBUNITS BETA-5I AND RPN-13 FOR ALTERNATIVE HEMATOLOGICAL CANCER THERAPIES CS Muli Purdue University Graduate School, 2024 | | 2024 |
| Discovery of the first-in-class SHP1 covalent inhibitor for cancer immunotherapy Z Qu, FN Meke, Z Zhang, Y Bai, AD Krabill, CS Muli, BA Jassim, J Dong, ... Cancer Research 84 (6_Supplement), 1973-1973, 2024 | | 2024 |
| High-throughput assay exploiting disorder-to-order conformational switches: application to the proteasomal Rpn10: E6AP complex CS Muli, SG Tarasov, KJ Walters Chemical science 15 (11), 4041-4053, 2024 | | 2024 |
